These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31829233)

  • 21. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
    Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze).
    Maheshwari A; Bell JL; Bhide P; Brison D; Child T; Chong HY; Cheong Y; Cole C; Coomarasamy A; Cutting R; Hardy P; Hamoda H; Juszczak E; Khalaf Y; Kurinczuk JJ; Lavery S; Linsell L; Macklon N; Mathur R; Pundir J; Raine-Fenning N; Rajkohwa M; Scotland G; Stanbury K; Troup S; Bhattacharya S
    Hum Reprod; 2022 Mar; 37(3):476-487. PubMed ID: 34999830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management.
    McLennan S; Griessbach A; Briel M;
    JAMA Netw Open; 2021 Jun; 4(6):e2111847. PubMed ID: 34076698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National expenditure on health research in South Africa: How has the landscape changed in the past decade?
    Barnabé MA; Gordon R; Ramjee G; Loots G; Blackburn JM
    S Afr Med J; 2020 Mar; 110(4):274-283. PubMed ID: 32657738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data.
    Speich B; von Niederhäusern B; Schur N; Hemkens LG; Fürst T; Bhatnagar N; Alturki R; Agarwal A; Kasenda B; Pauli-Magnus C; Schwenkglenks M; Briel M;
    J Clin Epidemiol; 2018 Apr; 96():1-11. PubMed ID: 29288136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop.
    Totton N; Julious SA; Coates E; Hughes DA; Cook JA; Biggs K; Hewitt C; Day S; Cook A
    Health Technol Assess; 2023 Oct; 27(20):1-58. PubMed ID: 37982521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis.
    Falk Delgado A; Falk Delgado A
    Trials; 2017 Mar; 18(1):125. PubMed ID: 28292317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
    Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An investigation of the impact of futility analysis in publicly funded trials.
    Sully BG; Julious SA; Nicholl J
    Trials; 2014 Feb; 15():61. PubMed ID: 24533447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Descriptive survey of non-commercial randomised controlled trials in the United Kingdom, 1980-2002.
    Chalmers I; Rounding C; Lock K
    BMJ; 2003 Nov; 327(7422):1017. PubMed ID: 14593034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials.
    Larson GS; Carey C; Grarup J; Hudson F; Sachi K; Vjecha MJ; Gordin F;
    Clin Trials; 2016 Apr; 13(2):127-36. PubMed ID: 26908541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paediatric clinical trials need paediatric clinical trial budgets.
    Koulizakos S; Kjellén T; Mellgren K; Kindblom JM
    Acta Paediatr; 2023 Sep; 112(9):1982-1985. PubMed ID: 37119385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial.
    Bracken K; Keech A; Hague W; Allan C; Conway A; Daniel M; Gebski V; Grossmann M; Handelsman DJ; Inder WJ; Jenkins A; McLachlan R; Robledo KP; Stuckey B; Yeap BB; Wittert G
    Clin Trials; 2019 Dec; 16(6):589-598. PubMed ID: 31581816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.